Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17574701 | 0.98 | POLB (0.37) | TSHRHPGDCA1CA2POLB | |
| SCHEMBL105392 | 0.86 | POLB (0.39) | TSHRHPGDCA1CA2POLB | |
| SCHEMBL19958495 | 0.81 | LMNA (0.45) | TSHRPOLBL3MBTL1NPSR1KMT2A | |
| SCHEMBL17574690 | 0.79 | PIK3CD (0.33) | TSHRKMT2AMAPTELOVL6 | |
| SCHEMBL1321117 | 0.78 | TSHR (0.44) | TSHRHPGDCA1CA2POLB | |
| SCHEMBL2817480 | 0.76 | L3MBTL1 (0.42) | TSHRHPGDCA1CA2POLB | |
| SCHEMBL6894873 | 0.76 | L3MBTL1 (0.42) | TSHRHPGDCA1CA2POLB | |
| SCHEMBL12847618 | 0.75 | EPHX2 (0.51) | TSHRHPGDCA1CA2POLB | |
| SCHEMBL13058141 | 0.75 | EPHX2 (0.51) | TSHRHPGDCA1CA2POLB | |
| SCHEMBL13013076 | 0.75 | L3MBTL1 (0.41) | TSHRHPGDCA1CA2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072726-A9 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20160068531-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068531-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | ZC3HAV1, IDO1, AZI2 | TSHR 1187/4885HPGD 3717/4885CA1 4553/4885 |
| US-20180072726-A9 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | ZC3HAV1, IDO1, AZI2 | TSHR 1187/4885HPGD 3717/4885CA1 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.